⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16741 | 0.93 | — | — | |
| SCHEMBL3667891 | 0.93 | — | — | |
| SCHEMBL7901642 | 0.86 | — | — | |
| SCHEMBL4594980 | 0.86 | — | — | |
| SCHEMBL3358625 | 0.86 | — | — | |
| Methane SCHEMBL7938760 | 0.86 | — | — | |
| Hydroxyamine SCHEMBL272868 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL3442206 | 0.86 | — | — | |
| Phosphine SCHEMBL20595760 | 0.86 | — | — | |
| Hydrogen Sulfide SCHEMBL3358284 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171635-A1 | NOVEL HYDRAZONE-BASED AND OXIME-BASED FLUORESCENT AND CHROMOPHORIC/PRO-FLUORESCENT AND PRO-CHROMOPHORIC REAGENTS AND LINKERS | SOLULINK BIOSCIENCES, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-8541555-B2 | Hydrazone-based and oxime-based fluorescent and chromophoric/pro-fluorescent and pro-chromophoric reagents and linkers | SOLULINK BIOSCIENCES, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20080221343-A1 | Labeled biomolecules of chromophore or the fluorophore incorporated into the linker between a reactive linking moiety and a biotin molecule; proteins, nucleic acids | AUDAX PRIVATE DEBT LLC, AS AGENT | 2008-09-11 | — | — | US | disclosed |
| US-20080051299-A1 | DNA-protein fusions and uses thereof | COMPOUND THERAPEUTICS INC. | 2008-02-28 | — | — | US | disclosed |
| US-7195880-B2 | DNA-protein fusions and uses thereof | ADNEXUS THERAPEUTICS, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| EP-1137812-B1 | DNA-PROTEIN FUSIONS AND USES THEREOF | ADNEXUS THERAPEUTICS INC (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20020177158-A1 | DNA-protein fusions and uses thereof | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-28 | — | — | US | disclosed |
| US-6416950-B1 | LINKING NUCLEIC ACID REVERSE TRANSCRIPTION PRIMER WHICH IS BOUND TO PEPTIDE ACCEPTOR TO RNA, TRANSLATING RNA TO PRODUCE PROTEIN PRODUCT COVALENTLY BOUND TO PRIMER, REVERSE TRANSCRIBING RNA TO PRODUCE DNA-PROTEIN FUSION | PHYLOS, INC. | 2002-07-09 | — | — | US | disclosed |
| EP-1137812-A4 | DNA-PROTEIN FUSIONS AND USES THEREOF | PHYLOS INC (US) | 2002-04-24 | — | — | EP | disclosed |
| EP-1137812-A1 | DNA-PROTEIN FUSIONS AND USES THEREOF | Phylos, Inc. (US) | 2001-10-04 | — | — | EP | disclosed |
| WO-2000032823-A9 | DNA-PROTEIN FUSIONS AND USES THEREOF | PHYLOS INC (US) | 2001-03-29 | — | — | WO | disclosed |
| WO-2000032823-A1 | DNA-PROTEIN FUSIONS AND USES THEREOF | PHYLOS, INC. (US) | 2000-06-08 | — | — | WO | disclosed |